{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:09:11Z","timestamp":1779923351959,"version":"3.53.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC2005601"],"award-info":[{"award-number":["2020YFC2005601"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U19A2002"],"award-info":[{"award-number":["U19A2002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["Z20191002 ZYJC21018"],"award-info":[{"award-number":["Z20191002 ZYJC21018"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>A cell-based transduction inhibition assay (TI) is widely used in clinical trials to detect neutralizing antibody (NAb) titers against recombinant adeno-associated virus (rAAV), one of the most important criteria to exclude patients in gene therapy. Different cell lines are used in cell-based TI because the rAAV transduction efficiencies vary largely among serotypes. A cell line suitable for TI for most serotypes is highly desirable, especially for those with very low transduction efficiencies <jats:italic>in vitro<\/jats:italic> such as rAAV8 and rAAV9. Herein, we report an AAVR-HeLa, a stable cell line with overexpressed AAVR, a newly identified receptor for rAAVs, was established for cell-based TIs. The AAVR expression level in AAVR-HeLa cells was approximately 10-fold higher than in HeLa cells, and was stably transfected after twenty three passages. For all AAV serotypes (AAV1-10), except for AAV4, the transduction efficiencies increased significantly in AAVR-HeLa cells. It was demonstrated that the AAVR enhancement of transduction efficiency was only for rAAV and not for lentiviral and adenoviral vectors. According to the minimal multiplicity of infection (MOIs) for the assay, the NAb detection sensitivity increased at least 10 and 20 fold for AAV8 and AAV9, respectively. The seroprevalence of NAbs were investigated at the 1:30 level as a cutoff value using AAVR-HeLa cells. It was shown that the seropositive rate for AAV2 was 87% in serum samples from 99 adults, followed by lower seropositive rates for AAV5 (7%), AAV8 (7%) and AAV9 (1%). Venn diagram analysis showed the presence of cross-reactivity of NAbs to two or three serotypes in 13 samples (13.1%). However, no patient was found to possess NAbs for all the four serotypes. These results demonstrated that the AAVR-HeLa cell line may be utilized to detect the NAbs through cell-based TI assays for most of AAV serotypes.<\/jats:p>","DOI":"10.3389\/fphar.2023.1188290","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T05:36:27Z","timestamp":1682573787000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Enhanced sensitivity of neutralizing antibody detection for different AAV serotypes using HeLa cells with overexpressed AAVR"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhaoyue","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Alexander","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi Yee","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.omtm.2021.06.004","article-title":"A sensitive and reproducible cell-based assay via secNanoLuc to detect neutralizing antibody against adeno-associated virus vector capsid","volume":"22","author":"Baatartsogt","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/humc.2013.087","article-title":"Lessons learned from the clinical development and market authorization of Glybera","volume":"24","author":"Bryant","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J. Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/sj.gt.3301710","article-title":"Replication competent helper functions for recombinant AAV vector generation","volume":"9","author":"Cao","year":"2002","journal-title":"Gene Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: Current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1002\/jmv.27859","article-title":"Age-stratified adeno-associated virus serotype 3 neutralizing and total antibody prevalence in hemophilia A patients from India","volume":"94","author":"Daniel","year":"2022","journal-title":"J. Med. Virol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.omtm.2021.02.014","article-title":"Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec","volume":"21","author":"Day","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/mt.2009.258","article-title":"Characterization of genome integrity for oversized recombinant AAV vector","volume":"18","author":"Dong","year":"2010","journal-title":"Mol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e13968","DOI":"10.15252\/emmm.202113968","article-title":"Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity","volume":"14","author":"Eggers","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/gt.2017.95","article-title":"Strategy to detect pre-existing immunity to AAV gene therapy","volume":"24","author":"Falese","year":"2017","journal-title":"Gene Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/mt.2015.151","article-title":"Genome engineering using adeno-associated virus: Basic and clinical research applications","volume":"24","author":"Gaj","year":"2016","journal-title":"Mol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.omtm.2018.11.007","article-title":"Rapid AAV-neutralizing antibody determination with a cell-binding assay","volume":"13","author":"Guo","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41434-019-0078-3","article-title":"Polarized AAVR expression determines infectivity by AAV gene therapy vectors","volume":"26","author":"Hamilton","year":"2019","journal-title":"Gene Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40265-023-01845-0","article-title":"Etranacogene dezaparvovec: First approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/73464","article-title":"Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector","volume":"24","author":"Kay","year":"2000","journal-title":"Nat. Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s40265-022-01775-3","article-title":"Eladocagene exuparvovec: First approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpn.2020.07.001","article-title":"European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy","volume":"28","author":"Kirschner","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1182\/blood-2010-08-302729","article-title":"Assessing the potential for AAV vector genotoxicity in a murine model","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"key":"B20","first-page":"379","article-title":"Humoral immunity to AAV vectors in gene therapy: Challenges and potential solutions","volume":"15","author":"Masat","year":"2013","journal-title":"Discov. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","article-title":"Integration of adeno-associated virus (AAV) and recombinant AAV vectors","volume":"38","author":"McCarty","year":"2004","journal-title":"Annu. Rev. Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.omtm.2019.03.004","article-title":"CRISPR activation enhances in vitro potency of AAV vectors driven by tissue-specific promoters","volume":"13","author":"Mcdougald","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/hgtb.2015.037","article-title":"Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system","volume":"26","author":"Meliani","year":"2015","journal-title":"Hum. Gene Ther. Methods"},{"key":"B24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: Rationale, lessons and future considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.tim.2021.09.005","article-title":"Adeno-associated virus (AAV) cell entry: Structural insights","volume":"30","author":"Meyer","year":"2022","journal-title":"Trends Microbiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/gt.2012.55","article-title":"Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue","volume":"20","author":"Mingozzi","year":"2013","journal-title":"Gene Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1093\/nar\/gkh593","article-title":"Expression of the adenovirus E4 34k oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell line","volume":"32","author":"Mohammadi","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature16465","article-title":"An essential receptor for adeno-associated virus infection","volume":"530","author":"Pillay","year":"2016","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.omtm.2020.03.007","article-title":"Site-Directed Mutagenesis Improves the Transduction Efficiency of Capsid Library-Derived Recombinant AAV Vectors","volume":"17","author":"Ran","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.2196\/resprot.5535","article-title":"Determination of anti-adeno-associated viral vector neutralizing antibodies in patients with heart failure in the cardiovascular foundation of Colombia (ANVIAS): Study protocol","volume":"5","author":"Rincon","year":"2016","journal-title":"JMIR Res. Protoc."},{"key":"B32","doi-asserted-by":"publisher","first-page":"108887","DOI":"10.1016\/j.jneumeth.2020.108887","article-title":"Retrograde gene transfer into neural pathways mediated by adeno-associated virus (AAV)-AAV receptor interaction","volume":"345","author":"Sano","year":"2020","journal-title":"J. Neurosci. Methods"},{"key":"B33","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/nbt1117-998","article-title":"First AAV gene therapy poised for landmark approval","volume":"35","author":"Smalley","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/genes10040289","article-title":"Vitro gene delivery in retinal pigment epithelium cells by plasmid DNA-wrapped gold nanoparticles","volume":"10","author":"Trigueros","year":"2019","journal-title":"Genes. (Basel)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: A long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.omtm.2018.09.003","article-title":"Adeno-associated virus neutralizing antibodies in large animals and their impact on brain intraparenchymal gene transfer","volume":"11","author":"Wang","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1089\/hum.2011.031","article-title":"Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors","volume":"22","author":"Wang","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/sj.gt.3302133","article-title":"Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo","volume":"10","author":"Wang","year":"2003","journal-title":"Gene Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"658399","DOI":"10.3389\/fimmu.2021.658399","article-title":"Anti-AAV antibodies in AAV gene therapy: Current challenges and possible solutions","volume":"12","author":"Weber","year":"2021","journal-title":"Front. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: Vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s11427-020-1744-6","article-title":"Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor","volume":"65","author":"Yin","year":"2022","journal-title":"Sci. China Life Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.omtm.2021.06.009","article-title":"Low endotoxin E. coli strain-derived plasmids reduce rAAV vector-mediated immune responses both in vitro and in vivo","volume":"22","author":"Zheng","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1188290\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T05:36:35Z","timestamp":1682573795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1188290\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":43,"alternative-id":["10.3389\/fphar.2023.1188290"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1188290","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"article-number":"1188290"}}